Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3282151 | Clinical Gastroenterology and Hepatology | 2013 | 8 Pages |
Abstract
Although a significantly higher percentage of patients who continue thienopyridine therapy during colonoscopy and polypectomy develop clinically important delayed PPB than patients who discontinue therapy, the rate of PPB events is low (2.4%), and all are resolved without sequelae. The risk for catastrophic cardiovascular risks among patients who discontinue thienopyridine therapy before elective colonoscopies could therefore exceed the risks of PPB. ClinicalTrials.gov, Number NCT01647568.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Linda A. Feagins, Ramiz Iqbal, William V. Harford, Akeel Halai, Byron L. Cryer, Kerry B. Dunbar, Raquel E. Davila, Stuart J. Spechler,